JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aghdassi, E.
Right arrow Articles by Allard, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aghdassi, E.
Right arrow Articles by Allard, J. P.
Journal of the American College of Nutrition, Vol. 25, No. 1, 56-63 (2006)
Published by the American College of Nutrition

Is Chromium an Important Element in HIV-Positive Patients with Metabolic Abnormalities? An Hypothesis Generating Pilot Study

Elaheh Aghdassi, PhD, Irving E. Salit, MD, Lillia Fung, BSc, Lavaniya Sreetharan, BSc, Sharon Walmsley, MD and Johane P. Allard, MD

Department of Medicine, The University Health Network, The Toronto General Hospital, Toronto, CANADA

Address reprint requests to: Dr. Johane P. Allard, The Toronto General Hospital, 200 Elizabeth St., Eaton Wing, 9th Floor, Room 217a, Toronto, Ontario, M5G-2C4, CANADA. E-mail johane.allard{at}uhn.on.ca

Background: Chromium plays a role in insulin sensitivity.

Objectives: To compare chromium measurements in HIV-positive patients with or without (N) antiretroviral therapy (ART) to that of healthy controls (HC) and, to determine if there is any association between chromium levels and abnormalities in body composition, glucose and lipid metabolism.

Design: A cross-sectional study in 91 HIV patients (75 HIV-ART, 16 HIV-N) and 13 HC. Chromium was assessed in the diet, plasma, toenails, and urine. Fasting blood glycemia and lipids, lipodystrophy score and body fat were also determined.

Results: Dietary intake of chromium was similar in the 3 groups. Plasma and toenail Cr were lower in HIV compared to HC, but urinary chromium was similar. However, when the HIV-positive patients on ART were compared to those who were naïve to therapies, urinary excretion of chromium was higher in HIV-ART. In addition, urinary excretion of chromium significantly and positively correlated with lipodystrophy score and negatively with various parameters of metabolic syndrome.

Conclusion: Despite a similar dietary intake, chromium levels were lower in HIV-positive patients and urinary chromium excretion correlated with some metabolic parameters. Low chromium levels may be due to increased chromium losses. These results support further studies on chromium in HIV patients.

Key words: chromium, HIV, glucose, lipid, lipodystrophy, body composition

Abbreviations: ART = antiretroviral therapy • BIA = bioelectric impedance analysis • Cr = chromium • HAART = highly active antiretroviral therapies • HC = healthy control subjects • HDL = high density lipoprotein • HIV = human immunodeficiency virus • IRI = insulin resistance index • LDL = low density lipoprotein • LS = lipodystrophy • N = HIV patient who is naïve to antiretroviral drugs • PI = protease inhibitors • TG = triglycerides






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Nutrition.